Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Abbott Reports Two Hepatitis C Relapses in ‘Pilot’ Trial

Few relapses were reported among patients taking Abbott Laboratories’ experimental hepatitis C treatment, according to a study.

The Abbott-funded research, dubbed Pilot, found that 10 of 11 patients who hadn’t received prior treatment were cured 24 weeks after the end of a 12-week treatment on the drugmaker’s hepatitis C drugs ABT-072 and ABT-450 with ribavirin, the Abbott Park, Illinois-based company said today in a statement.

After 36 weeks, another patient relapsed, while no more relapses were observed after 48 weeks, the company said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.